José Manuel López-Vega

Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells

Pedro J. Real, Àngels Sierra, Ana De Juan et al. · Oncogene · 2002 · 321 citations

Medicine, Cancer Biology, Oncology +14

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Miguel Martín, Álvaro Rodríguez-Lescure, A. Ruiz et al. · JNCI Journal of the National Cancer Institute · 2008 · 239 citations · Full text

Medicine, Oncology, Pharmacology +15

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí et al. · Annals of Oncology · 2006 · 204 citations · Full text

Medicine, Oncology, Pharmacology +17

Motor neuron disease in Cantabria

José Manuel López-Vega, Jesús Calleja, Onofre Combarros et al. · Acta Neurologica Scandinavica · 1988 · 107 citations

Medicine, Neurology, Neuroscience +17

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

Miguel Martín, Aleix Prat, Álvaro Rodríguez-Lescure et al. · Breast Cancer Research and Treatment · 2013 · 102 citations · Full text

Medicine, Oncology, Pharmacology +17